LivaNova PLC (NASDAQ:LIVN) Position Boosted by Texas Permanent School Fund Corp

Texas Permanent School Fund Corp boosted its position in LivaNova PLC (NASDAQ:LIVN) by 4.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,086 shares of the company’s stock after buying an additional 1,939 shares during the quarter. Texas Permanent School Fund Corp owned approximately 0.09% of LivaNova worth $2,691,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. New York State Teachers Retirement System raised its position in shares of LivaNova by 0.3% during the 1st quarter. New York State Teachers Retirement System now owns 64,322 shares of the company’s stock worth $3,598,000 after purchasing an additional 200 shares during the period. Arizona State Retirement System grew its holdings in LivaNova by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock worth $828,000 after buying an additional 299 shares in the last quarter. State of Michigan Retirement System increased its position in LivaNova by 2.3% in the 1st quarter. State of Michigan Retirement System now owns 13,211 shares of the company’s stock valued at $739,000 after acquiring an additional 300 shares during the period. Fifth Third Bancorp grew its position in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after buying an additional 332 shares in the last quarter. Finally, Hexagon Capital Partners LLC boosted its holdings in shares of LivaNova by 117.8% in the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after acquiring an additional 370 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

LIVN has been the topic of several recent research reports. Robert W. Baird restated a “neutral” rating and issued a $55.00 price target on shares of LivaNova in a research report on Wednesday, August 28th. Stifel Nicolaus lifted their target price on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, Needham & Company LLC increased their price objective on LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, LivaNova currently has an average rating of “Moderate Buy” and a consensus target price of $68.60.

LivaNova Price Performance

Shares of LIVN opened at $48.79 on Tuesday. The stock has a market cap of $2.65 billion, a P/E ratio of -81.32 and a beta of 1.00. The stock’s 50-day moving average price is $48.85 and its two-hundred day moving average price is $53.47. The company has a current ratio of 3.45, a quick ratio of 2.94 and a debt-to-equity ratio of 0.49. LivaNova PLC has a 1 year low of $42.75 and a 1 year high of $64.47.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.66 by $0.15. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The firm had revenue of $318.60 million for the quarter, compared to the consensus estimate of $305.05 million. On average, equities analysts predict that LivaNova PLC will post 2.58 earnings per share for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.